Pliant Therapeutics Announces Repricing of Underwater Stock Options for Employees and Executives

Pliant Therapeutics, Inc. (NASDAQ: PLRX) has announced a significant development that may impact its share price and is of material interest to shareholders: the company’s Board of Directors has approved a comprehensive repricing of underwater stock options held by employees, including its executive team.

Key Details of the Option Repricing

• Approval and Effective Date: The repricing was approved by the Board on April 15, 2026, following a recommendation from its Compensation Committee. The repricing becomes effective on April 17, 2026.
• Scope of Repricing:
  The repricing affects all stock options granted on or before March 1, 2025, under the company’s
  • 2015 Equity Incentive Plan (as amended),
  • 2020 Stock Option and Incentive Plan (as amended), and
  • 2022 Inducement Plan (as amended).

  Only employees who hold these options as of the effective date are eligible, including the company’s executive officers.

• Executive Officers Involved:
  The repricing includes options held by the following top executives:
  • Bernard Coulie, M.D., Ph.D. – President and Chief Executive Officer
  • Keith Cummings, M.D., MBA – Chief Financial Officer
  • Lily Cheung – Chief Human Resources Officer
  • Minnie Kuo – (Other listed executive officer)
• Reason for Repricing:
  The company’s entire current employee population held “underwater” options—meaning the exercise price was higher than the prevailing market price of PLRX common stock.

Rationale and Potential Impact

• Retention and Motivation:
  The main objective of this repricing is to retain and motivate key employees and executives during a critical stage for the company’s development. The Board, after extensive discussion and consultation with an independent compensation consultant and outside legal counsel, determined this approach was preferable to issuing new equity or increasing cash compensation—which would either dilute shareholders or impact cash reserves.
• Shareholder Dilution Avoided:
  The company explicitly states that this repricing was designed to avoid additional dilution from new equity grants and to prevent further cash outflows from additional cash compensation.
• “Underwater” Options:
  At the time of approval, all outstanding options to employees were underwater, underscoring the need for action to ensure the incentive value of these awards. The repricing resets the incentive structure, aiming to realign employee and executive interests with shareholder value.

What Shareholders Need to Know

• This repricing is a material event and may influence the share price of PLRX. It is designed to address a widespread issue among the workforce and management, strengthening retention and motivation without resorting to new share issuance or cash payments.
• No immediate dilution or cash cost: The repricing does not increase the number of shares outstanding or require additional cash outlay. However, if the company’s share price recovers, employees and executives will benefit more directly from rising share values.
• Potential Perception Impact: While repricing can be viewed positively as an alignment of interests, some investors may perceive it as a sign of past performance struggles or may weigh the impact on executive compensation structures.

Other Administrative Details

• The filing confirms that Pliant Therapeutics is not currently an “emerging growth company.”
• The company’s common stock trades on the NASDAQ under the symbol PLRX.
• There are no other simultaneous filings or communications under Securities Act Rule 425, Soliciting Material, or Pre-commencement Tender Offer communications.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are urged to review the full SEC filing and consult with their financial advisor before making any investment decisions. The information provided herein is based on the company’s Form 8-K filed April 17, 2026, and subsequent disclosures. Market reactions to repricing events may vary significantly based on investor perception and broader market conditions.

View PLIANT THERAPEUTICS, INC. Historical chart here